The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
As hepatitis outbreaks continue, CDC may urge HBV shot for millions of diabetics
Landmark recommendation expected from ACIP
By Gary Evans, Executive Editor
A key advisory committee to the Centers for Disease Control and Prevention is expected to recommend that millions of diabetics be immunized against hepatitis B virus, a move that could finally halt the recurrent and deadly HBV outbreaks linked to needles and devices used in glucose monitoring in a variety of healthcare settings, Hospital Infection Control & Prevention has learned.
The CDC Advisory Committee on Immunization Practices (ACIP), which has been mulling the issue for more than a year, will likely make the recommendation to immunize diabetics for HBV at an October 25-26, 2011 meeting in Atlanta, says William Schaffner, MD, an ACIP liaison member representing the National Foundation for Infectious Diseases.
"These outbreaks of hepatitis B occurring in hospitals and other health care facilities — including nursing homes and assisted living facilities — have really come to the attention of ACIP," he says. "If that is the way the vote goes — and everybody thinks it's going that way — this [importance of HBV vaccination] will have to be intensely educated to people with diabetes and everyone taking care of patients with diabetes," he says. "It will have to be put on the list of quality assurance measures for the care of diabetic patients so we know that doctors actually do this."
In addition to HBV, outbreaks linked to blood glucose testing carry the threat of hepatitis C virus and HIV, neither of which have a vaccine. Though accurate surveillance data for these kind of outbreaks are notoriously elusive, it does appear from the ongoing outbreaks that HBV is the prime threat of being transmitted via reused or improperly handled equipment. HBV is the most efficient transmitter of the common bloodborne viruses, its high-titer counts in blood residue easily persisting in the environment for days on inadequately disinfected equipment and surfaces.
"In patients who have diabetes it's important that they monitor their blood glucose level in order to determine the correct concentration and frequency of insulin administration," explains Alice Guh, MD, MPH, a medical epidemiologist in the CDC's Division of Healthcare Quality Promotion. "The concern is when devices used to administer insulin and to check for blood glucose are not appropriately handled. That's certainly when we become concerned."
In one of the more compelling arguments to widely administer the HBV vaccine, it must be duly noted that the CDC has had a standing recommendation that glucose fingerstick devices be restricted to individual use for more than 20 years. Yet this advice is ignored all too frequently, most recently in a clinic in Madison, WI where thousands of patients are being evaluated for testing. It's a familiar, traumatic refrain. In outbreaks previously reported by HIC, infection control breaches included reusing spring-loaded barrels of fingerstick devices for multiple patients, sharing the fingerstick devices among patients and/or staff routinely administering the sticks without wearing gloves or performing hand hygiene between patients.
"Insulin pens really should be viewed in the same way that we see syringes and needles — this type of equipment should be dedicated to single patients use," Guh says. "A diabetic patient — whether they are checking their blood glucose levels or if they are being assisted by someone else — the fingerstick device should really be a single use, disabling type of device where the lancet could retract and provide an extra layer of safety and [ensure] the device can't be used again." (See CDC recommendations, below.)
|CDC recommendations for HBV vaccination|
Who should be vaccinated against Hepatitis B? The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices currently recommends that the following persons be vaccinated against Hepatitis B:
Though the threat of other bloodborne viruses would remain, a large HBV vaccination campaign in the diabetic population could disable a great threat to patient safety.
"I think it would be very substantial — it ought to essentially eliminate many of these outbreaks," says Schaffner, chairman of the department of preventive medicine at Vanderbilt University School of Medicine Nashville.
"While we at Vanderbilt and other places are doing a better job with infection control with these glucometers, the general sense is 'OK that's very good — but it's not sufficient,'" he adds. "The number of outbreaks that have occurred — particularly among older people — both in hospitals and in other health care facilities is substantial."
While most of the reported outbreaks have occurred in non-hospital settings, state and federal authorities are ratcheting up pressure in acute care — demanding strict infection control policies with glucose monitoring equipment. Though Vanderbilt thought they had an adequate program in place, Tennessee state health department inspectors decided the hospital needed to upgrade cleaning and documentation for blood glucose meters.
"That [state] survey brought this home to us in a very explicit fashion," Schaffner says. "We knew that glucometers were being used and we made the assumption that they were being used appropriately, but we clearly had to demonstrate to the surveyors that we had a very rigorous program in place on glucometer use and glucometer disinfection between patients. We had to be able to document that. We really jumped on that and put a lot of energy into it."
At the top of the agenda
The HBV immunization issue tops the agenda for the upcoming ACIP meeting, with the first two items listed being "HBV risk among adults with diabetes" and "assisted blood glucose monitoring." The latter term may essentially be a surrogate for higher risk of infection, as "assisted monitoring of blood glucose is typically performed in healthcare settings such as clinics, hospitals, and long-term care settings (e.g., skilled nursing facilities and assisted living facilities). Individuals who perform blood glucose monitoring either for themselves or on others must be aware of basic safe practices to protect against infection transmission," the CDC states.
There have been numerous jarring exceptions to that rule, resulting in at least 16 outbreaks of HBV infection in the United States since 2004 — all linked to sharing or other inappropriate reuse of blood glucose monitoring equipment in assisted-living facilities.1 However, earlier this year the CDC reported an outbreak that may have tipped the scales. To put it bluntly, six diabetics who died of HBV complications would likely be alive today if they had been vaccinated against the virus. On October 12, 2010, the North Carolina public health officials were alerted by a local hospital that they had four residents of a single assisted-living facility admitted with suspected acute HBV infection. The resulting investigation found unsafe practices at the facility, including sharing of reusable fingerstick lancing devices approved for single patient use only and shared use of blood glucose meters without cleaning and disinfection between patients. And here, another telling point: None of the 25 residents who had not been assisted with blood glucose monitoring were infected. However, eight of the 15 residents whom facility staff had assisted with blood glucose monitoring had HBV infections. Note the staggering attack rate of greater than 50%, and again six patients died.
HBV prevalence across broad spectrum
In the North Carolina case, safety single-use devices were required at the facility and HBV vaccine was offered to all susceptible residents. Now ACIP is poised to recommend that CDC do the same thing nationally, but something has also bubbled to the surface as the data were gleaned. While one of the original discussion points on this issue was whether to just vaccinate diabetics in long-term care, ACIP has found a striking HBV prevalence throughout age groups.
"As they have investigated this further, [ACIP found] that at every age going down to young adulthood, diabetics have a higher rate of HBV than their non-diabetic counterparts, [even when] controlled by age, demographics and every other way you can control," Schaffner says.
Why? One possibility has something to do with the small part of an iceberg at its highest point above water. As infection preventionists are well aware, the reported outbreaks of HBV and HCV are certainly dwarfed by the unreported ones and the sporadic transmission moving under the radar. These infections may be counted among hepatitis cases of unknown origin, though some health departments and IPs at times make heroic efforts to try to find a health care connection. For example, the CDC reports that in 2006, national viral hepatitis surveillance data revealed that 50% of patients with acute HBV and HCV were reported without accompanying risk factor data.2 Among patients for whom risk factor data were reported, 56% with acute HBV infection and 32% with acute HCV infection could not specify a known risk factor for their infection (such as injection drug use, sexual or household contact with another infected person, occupational exposure to blood, or needlestick injury.) A published CDC review of outbreak information revealed 33 outbreaks in nonhospital health care settings in the prior decade, including 12 in outpatient clinics, six in hemodialysis centers, and 15 in long-term care facilities, resulting in 448 people acquiring HBV or HCV infection.3 The data did not include specific information of the subset of diabetics, but one is tempted to conclude that much of the HBV prevalence in the population may be linked to healthcare settings.
"It has been a struggle to understand this — obviously diabetics as a group have much more exposure to needles," Schaffner says. "There is this sense of needle sharing, [is that] where does this increased risk of HBV come from? That remains an enigma, but every way you parse it — to everyone's surprise — these investigations have found the increased risk remained."
With the nation's obesity epidemic expected to fuel a continuing increase, there are some 26 million diabetics in the U.S. — roughly 8% of the population — and 7 million of them have yet to be diagnosed. The prevalence of HBV in diabetic populations will no doubt be detailed at the ACIP meeting, but unpublished CDC data provided to the committee previously reveals that diabetics comprise some 10% of all HBV infections in adults age 25 years and older. The other compelling factor for vaccination is the bad outcomes in patients where these diseases converge. Increases in liver-associated hospitalizations and all-cause mortality with chronic HBV, are reported among adults with diabetes and hepatitis. Knowing that at least some of these disturbing patient outcomes were caused by viral transmission in medical or long term care settings, puts an ethical onus on ACIP to act. For Schaffner, it's a no brainer. Hepatitis vaccination should include diabetics and everybody else.
"There isn't any doubt about it — we ought to immunize young adults [for HBV] universally," he says. "We have kind of a schizophrenic immunization policy in the United States. Up until the 19th birthday we immunize universally for HBV and then beyond that it remains a traditional risk-based immunization program."
Though the latest CDC recommendations state that anyone can be immunized that wants to get the vaccine, Schaffner says for all practical purposes a perfectly good vaccine has been historically undermined by unnecessary risk assessments prior to administration.
"You have to, in effect, `qualify' for hepatitis B immunization," he tells HIC. "It seems kind of paradoxical because young adults are just entering that period of more widespread sexual activity. You have to go to the doctor and say I have multiple sex partners or one thing or another. You have to qualify by having had some exposure before you can get immunized."
Despite such concerns, he concedes that ACIP is not likely to go beyond diabetics in recommendations to the CDC. "I don't think ACIP is ready yet to just advance universal immunization until age 30 or 40 or whatever it might be established more or less arbitrarily," Schaffner says. "But [a recommendation to immunize diabetics] would extend the protection against HBV to a very large and obviously growing segment of the population."